Inhibiting USP13 for NSCLC

Inhibiting USP13, a KRAS-driven deubiquitinase that stabilizes the transcription factor β-catenin by cleaving a polyubiquitin chain that tags it for proteasomal degradation, could help treat NSCLC by decreasing downstream activation of the metastasis-driving transcription factor TCF4 and intermediate filament protein vimentin.  

In bioinformatic analyses of publicly available genomic data from patients, USP13 was the most amplified deubiquitinase in lung cancers, and amplification occurred more frequently in lung cancer than other cancer types...